Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial

Clicks: 393
ID: 268259
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #1 of 4 articles by views in european journal of heart failure

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
NCT01065194.
Reference Key
j2014europeanefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Altenberger J;Parissis JT;Costard-Jaeckle A;Winter A;Ebner C;Karavidas A;Sihorsch K;Avgeropoulou E;Weber T;Dimopoulos L;Ulmer H;Poelzl G;;
Journal european journal of heart failure
Year 2014
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/24920349
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't female male aged middle aged 80 and over Randomized Controlled Trial Double-Blind Method Multicenter Study severity of illness index disease-free survival intravenous infusions quality of life ambulatory care* heart failure / drug therapy* simendan hydrazones / therapeutic use* pyridazines / therapeutic use* pmid:24920349 doi:10.1002/ejhf.118 johann altenberger john t parissis gerhard poelzl cardiotonic agents / therapeutic use*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.